Enovita®
Browse all Indena’s documents about products, events, company information and so much more.
Go to section
See through science
Enovita®
Scroll to see more
Peer-reviewed science on Enovita®
Clinically proven on healty subjects
The most recent study on Enovita® included 80 healthy participants that were randomized to receive GSE supplementation or placebo twice a day for a total of 16 weeks. The principal endpoints included pressure modulation and the perception of stress and worries.1
Effective in reducing perceived stress and worries
Enovita® supplementation is associated with a general increase of mental quality of life (quality of life questionnaire SF-12 and mental component summary MCS12).1
Figure 1. Results from SF-12 self-administered questionnaire.
Also the perception of worries under Enovita® supplementation was less pronounced (Figure 2).
Figure 2. Results from PSQ self-administered questionnaire at baseline, after 8 and 16 weeks. (Validated tool to assess subjectively experienced stress independent of a specific or objective occasion). Graphic elaboration of table 2, form ref. 1.
Promotes the maintenance of normal blood pressure1
Enovita® significantly modulated both systolic and diastolic pressurewith a dose-dependent effect.1
Figure 3. A favorable effect of systolic blood pressure was observed in all groups, but the effect was significantly higher in the treatment group (p < 0.05). The effect was lower for the diastolic pressure. Thus, in the two treatment groups, an effect on the diastolic pressure was also observed and developed more gradually in time.1
Blood pressure at normal range in cardiac stress2
Enovita® can have beneficial cardiovascular effects that may support intervention strategies in cardiac stress.
In a human study, after 4 months of administration, a statistically significant, and dose-dependent, amelioration in all endpoints (systolic pressure, diastolic pressure, laser doppler flux, heart rate, plasma-free radicals) is observed in both groups delivered with Enovita® compared to the not delivered one, with blood pressure normalizing in 93% of the higher dosage (300mg) administrated group. Taken together, these observations suggest that Enovita® have beneficial cardiovascular effects that may support current management strategies in the hypertension area.
[TABLE TITLE] Systolic pressure, diastolic pressure, laser doppler flux, heart rate, plasma-free radicals in 2 Enovita® administrated groups (300 mg and 150 mg) and a not administrated one, at inclusion, 4, 8, 12, and 16 weeks.
[TABLE TITLE] Subjects compliance and tolerability at the end of the trial.
BIBLIOGRAPHY
1Schön C, et al. Nutrients. 13(2):654. (2021)
2Belcaro G., Ledda A., Hu S., et al., Evidence-Based Complementary and Alternative Medicine, ID 313142 (2013).
